Scholarly publications and presentations by Rochester Regional Health's Allergy and Immunology department authors.

Follow


Submissions from 2023

Link

2-7-2023          Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review, Stephen Jolles, Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom., Sergio Giralt, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Tessa Kerre, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium., et al.

Link

2-1-2023          A Randomized Trial of Penicillin Skin Testing Versus 2-Step Direct Challenge for Penicillin Allergy During Pregnancy, Allison Ramsey, Rochester Regional Health and S. Shahzad Mustafa, Rochester Regional Health

Link

2-1-2023          Comparisons of Structure, Stability, and IgE Cross-Reactivity among Cashew, Pistachio, Walnut, and Peanut Vicilin-Buried Peptides, Alexander Foo, National Institute of Environmental Health, Jacqueline Nesbit, USDA, Stephen Gipson, USDA SRRC, et al.

Link

2-1-2023          Drug Allergy Assessments in Older Adults: A Multi-Site Prospective Study from the United States Drug Allergy Registry, John Accarino, Massachusetts General Hospital, Allison Ramsey, Rochester Regional Health, Upeka Samarakoon, Massachusetts General Hospital, et al.

Link

2-1-2023          Outcome of Electronic-Consults and Facilitated Follow-up for Inpatient Asthma Exacerbations, Linh-An Tuong, Rochester Regional Health, Allison Ramsey, Rochester Regional Health, Peter Capucilli, Rochester Regional Health, et al.

Link

2-1-2023          Peanut (Arachis hypogaea) Allergen Powder-dnfp Manufacturing Including Standardization Of Allergen Potency, Stephen Tilles, Aimmune Therapeutics, a Nestlé Health Science company, Stephanie Leonard, University of California San Diego, Rady Children's Hospital, Paul T. Jedrzejewski, Medical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States., et al.

Link

1-1-2023          Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology, Nina Shah, Department of Medicine, University of California San Francisco, San Francisco, CA, United States.; S Shahzad Mustafa, Rochester Regional Health; and Donald C. Vinh, Department of Medicine, McGill University Health Centre, Montreal, Canada.

Link

1-1-2023          Teleallergy: Where Have We Been and Where Are We Going?, Allison Ramsey, Rochester Regional Health, Ann Chen Wu, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass., Bruce G. Bender, National Jewish Health, Denver, Colo., et al.

Link

1-1-2023          Transitioning individuals with peanut allergy from US Food and Drug Administration-approved peanut oral immunotherapy to a dietary peanut product, S Shahzad Mustafa, Rochester Regional Health and Jodi Shroba, Allergy and Immunology, Children's Mercy Hospital, Kansas City, Missouri.

Submissions from 2022

Link

12-1-2022          Bringing Data to Bear on the Mushy Middle: Riskier Immediate Reactions to Penicillin, Cosby A. Stone, Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. and Allison Ramsey, Rochester Regional Health

Link

12-1-2022          Effects of oral immunotherapy on immune tolerance, Peter Capucilli, Rochester Regional Health and David A. Hill, Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics and Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Link

12-1-2022          Immunosuppression in Patients With Primary Immunodeficiency-Walking the Line, S Shahzad Mustafa, Rochester Regional Health; Nicholas L. Rider, Liberty University College of Osteopathic Medicine and the Liberty Mountain Medical Group, Lynchburg, Va.; and Stephen Jolles, Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.

Link

12-1-2022          Primum Non Nocere, Marcus Shaker, Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Dartmouth Geisel School of Medicine, Hanover, NH. and Allison Ramsey, Rochester Regional Health

Link

12-2022          Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies, Anthony J. Ocon, Rochester Regional Health, Kate E. Ocon, University of Rochester Medical Center, Rochester, NY, Jennifer Battaglia, University of Rochester Medical Center, Rochester, NY, et al.

Link

11-1-2022          Air Pollution Effects in Allergies and Asthma, Anil Nanda, University of Texas Southwestern Medical Center, Dallas, TX, Syed Shahzad Mustafa, Rochester Regional Health, Maria Castillo, University of Texas Southwestern Medical Center, Dallas, TX, et al.

Link

11-1-2022          Allergy Electronic Health Record Documentation: A 2022 Work Group Report of the AAAAI Adverse Reactions to Drugs, Biologicals, and Latex Committee, Autumn C Guyer, Eric Macy, Andrew A White, et al.

Link

11-1-2022          Evaluating Pediatric Penicillin Allergy-The Need to Broaden Indications and Improve Access, S Shahzad Mustafa, Rochester Regional Health and Allison C. Ramsey, Rochester Regional Health

Link

10-11-2022          Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp, Stephanie A. Leonard, Division of Pediatric Allergy / Immunology, University of California San Diego, Rady Children's Hospital, San Diego, CA, United States., Yasushi Ogawa, Medical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States., Paul T. Jedrzejewski, Medical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States., et al.

Link

9-2022          Peanut oral immunotherapy: Reconsidering a one-size-fits-all approach, Lakshmi G. Nair, Rochester Regional Health and Peter Capucilli, Rochester Regional Health

File

6-9-2022          Contact Dermatitis, Linh-An Tuong, Rochester Regional Health

Link

6-9-2022          Penicillin Allergy and Perioperative Anaphylaxis, Allison Ramsey, Rochester Regional Health

Link

6-2022          Should children with immunoglobulin E–mediated food allergy be screened for eosinophilic esophagitis?, Peter Capucilli, Rochester Regional Health, Allison Ramsey, Rochester Regional Health, Linh-An Tuong, Rochester Regional Health, et al.

Link

5-23-2022          Patient and Clinician Attitudes Towards Telemedicine for Allergy and Immunology, Allison Ramsey, Rochester Regional Health; S Shahzad Mustafa, Rochester Regional Health; and Jay Portnoy, Section of Allergy, Asthma & Immunology. Children's Mercy Hospital, Kansas City, MO

Link

5-9-2022          Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice, Jay Portnoy, Section of Allergy, Asthma & Immunology. Children's Mercy Hospital, Kansas City, MO, United States., Christina E. Ciaccio, Section of Allergy/Immunology and Pediatric Pulmonology, The University of Chicago, Chicago, IL, United States., Janet Beausoleil, Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, United States., et al.

Link

5-2022          Telemedicine in Drug Hypersensitivity, Deva Wells; Katherine L. DeNiro; and Allison Ramsey, Rochester Regional Health